2008
April
Janis and Friends Forum: Read and Comment on EASL
Coverage.
VX950
Protease Inhibitor Telaprevir
New HCV Drugs Panel Discussion at EASL 2008
Safety of the HCV Protease Inhibitor TMC435350 in
Healthy Volunteers and Safety and Activity in Chronic Hepatitis C Infected
Individuals: A Phase I Study
HCV Protease Inhibitor Telaprevir, PROVE1 Study: final
results of a phase 2 study with peginterferon plus ribaviron in
treatment-naive patients with hepatitis C -
ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE
INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA
AND LIVER -
Interim Results from HCV SPRINT-1: RVR/EVR from Phase
2 Study of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in
Treatment-Naive Subjects with Genotype-1 CHC
DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1
INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL
POTENCY
Boceprevir (NS3 Protease Inhibitor) Combination
Therapy in Non Responders: Phase II Dose Finding Study
-
Sustained Viral Response Is Dependent On Baseline
Characteristics In The Re-treatment Of Previous Interferon/Ribavirin
Non-responders: Final Results From The EPIC3 Program
Romark Announces Presentation of New Data For
Nitazoxanide in Chronic Hepatitis C at EASL 2008
-
Pharmasset Presents Results of 4-Week Combination
Study of R7128 for the Treatment of Chronic Hepatitis C
-
Potent Antiviral Activity of 2nd Generation
HCV Nucleotide Inhibitors, IDX102 and IDX184, in HCV-infected Chimps
In Vitro Activity and Pharmacologic Properties of Two
Novel Series of HCV Protease Inhibitors -
Efficacy and safety of increasing doses of the
cyclophilin inhibitor Debio 025 in combination with pegylated interferon
alpha-2a in treatment naive chronic HCV patients
-
Safety of the HCV Protease Inhibitor
TMC435350 in Healthy Volunteers and Safety and Activity in Chronic Hepatitis
C Infected Individuals: A Phase I Study
InterMune Provides Additional Information on
ITMN-191 (R7227) MAD Study Results
ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE
INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA
AND LIVER -
Telaprevir plus Pegylated Interferon and Ribavirin
Allows Shorter Therapy for Patients with Genotype 1 HCV
Gilead Announces 72-Week Data from Pivotal Studies of
Tenofovir (Viread) for Chronic Hepatitis B
Biolex Therapeutics Researchers Present Locteron(R)
Phase 2a Hepatitis C Trial Results at EASL Conference
Pharmasset Adds Two Cohorts to R7128
Hepatitis C Study
Vertex reports promising hepatitis C drug
results
Vertex Telaprevir HCV Protease
Inhibitor Could Be A Winner; 2.5 million untreated/undiagnosed
Valeant Reports Promising 12-week Phase IIb Data on
Taribavirin
-
Vertex and Tibotec Start Phase 3 Study of Telaprevir
for Treatment-Naive Genotype 1 Hepatitis C Patients
OctoPlus Initiates Phase IIa Study of Locteron
Controlled-release Interferon
March-February
HCV Therapy: TT-033, novel RNA interference
product Oncolys and Tacere partner in hepatitis C drug development
Human Genome Shares Dip on Drug Outlook
The way forward in HCV treatment - finding the right path: New HCV Drugs,
resistance -
Vertex to Start Phase 3 Trials of HCV Protease
Inhibitor Telaprevir (VX-950)
Jan
Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir,
Investigational Hepatitis C Protease Inhibitor
Albuferon Dose in Ongoing Trials is Lowered Due to
Safety Concerns
InterMune Announces Continuing Progress on HCV Protease Inhibitor ITMN-191
(R7227)
Anadys Pharmaceuticals Announces Positive Results for
ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week
Combination Study for the Treatment of Chronic Hepatitis C
|
